The authors declare that they have no competing interests.
LN, OK, and MR included in the text the clinical data and gave the final approval of the manuscript version. FC participated to the treatment decision and gave his approval of the final manuscript version after revising it critically. EC and CN wrote the manuscript draft and gave their final approval to the modified text. All authors read and approved the final manuscript.
Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported.
We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months.
This case suggests new perspectives for the treatment of asbestosis and its systemic features.
Cullinan P, Reid P. Pneumoconiosis. Prim Care Resp J. 2013;22:249–52.
Otsuki T, Maeda M, Murakami S, Hayashi H, Miura Y, Kusaka M, et al. Immunological effects of silica and asbestos. Cell Mol Immunol. 2007;4:261–8. PubMed
Mattson SB. Caplan's syndrome in association with asbestosis. Report of a case. Scand J Respir Dis. 1971;52:153–61. PubMed
Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21:313–20. PubMed
Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol. 1993;150:4188–96. PubMed
- Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
- BioMed Central
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II